Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

@article{Alvarado2002PilotSO,
  title={Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia},
  author={Yesid Alvarado and Apostolia-Maria Tsimberidou and Hagop M Kantarjian and Jorge E. Cortes and Guillermo Garcia-Manero and Stefan H Faderl and Deborah A. Thomas and Elihu Estey and Francis J Giles},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2002},
  volume={51},
  pages={87-90}
}
Abstract Purpose. Mylotarg has moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myelogenous leukemia (AML). A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML. Methods. Mylotarg was administered at 6 mg/m2 intravenously on days 1 and 15, idarubicin 12 mg/m2 daily on days 2 through 4… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2001
View 13 Excerpts
Highly Influenced

Effects of Mylotarg (gemtuzumab ozogamicin) in combination with standard induction chemotherapy in the treatment of acute myeloid leukaemia: a feasibility study (abstract)

JW Kell, AK Burnett, R Chopra, J Yin
Blood 98:123a • 2001
View 4 Excerpts
Highly Influenced

Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine in patients with acute myeloid leukemia (abstract)

S Durrant, MW Schuster, +6 authors M Berger
Proc ASCO • 2002
View 1 Excerpt

Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) (abstract)

E Stadtmauer, R Larson, +7 authors F Appelbaum
Blood • 2001
View 1 Excerpt

Non-fatal venoocclusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin) (abstract)

A Langston, B Fienstein, +6 authors A Jones
Blood 98:201b • 2001
View 1 Excerpt

Phase II study of Mylotarg plus troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

F Giles, G Garcia-Manero, S O’Brien, EH Estey, H Kantarjian
Blood 98:212b • 2001
View 1 Excerpt

Similar Papers

Loading similar papers…